Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd trimmed its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 13.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 16,755 shares of the life sciences company's stock after selling 2,545 shares during the quarter. Y Intercept Hong Kong Ltd's holdings in Illumina were worth $1,329,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Freedom Investment Management Inc. boosted its position in Illumina by 3.7% during the fourth quarter. Freedom Investment Management Inc. now owns 2,856 shares of the life sciences company's stock valued at $382,000 after purchasing an additional 101 shares in the last quarter. Probity Advisors Inc. boosted its stake in Illumina by 12.2% in the fourth quarter. Probity Advisors Inc. now owns 2,054 shares of the life sciences company's stock valued at $274,000 after acquiring an additional 224 shares in the last quarter. Xponance Inc. raised its position in Illumina by 1.0% during the 1st quarter. Xponance Inc. now owns 26,762 shares of the life sciences company's stock worth $2,123,000 after buying an additional 264 shares during the last quarter. Rakuten Securities Inc. lifted its stake in Illumina by 290.3% during the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock valued at $29,000 after acquiring an additional 270 shares during the period. Finally, HighPoint Advisor Group LLC lifted its stake in Illumina by 15.9% during the 4th quarter. HighPoint Advisor Group LLC now owns 2,121 shares of the life sciences company's stock valued at $283,000 after acquiring an additional 291 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently issued reports on ILMN. Guggenheim decreased their target price on shares of Illumina from $122.00 to $114.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Evercore ISI upped their target price on Illumina from $116.00 to $128.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 8th. Scotiabank downgraded Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 price target for the company. in a report on Friday, July 11th. JPMorgan Chase & Co. dropped their price objective on shares of Illumina from $120.00 to $85.00 and set a "neutral" rating on the stock in a research note on Friday, May 9th. Finally, Stephens reiterated an "overweight" rating and issued a $105.00 target price on shares of Illumina in a research note on Tuesday, May 20th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Illumina has a consensus rating of "Hold" and an average target price of $125.11.

Illumina Price Performance

ILMN stock traded up $1.66 during trading on Friday, reaching $109.30. 1,937,527 shares of the company were exchanged, compared to its average volume of 2,248,812. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.48 and a current ratio of 1.86. The company has a market cap of $17.30 billion, a P/E ratio of -18.01, a PEG ratio of 2.14 and a beta of 1.36. The stock's 50 day moving average price is $91.50 and its 200 day moving average price is $93.77.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.96 by $0.01. The firm had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.03 billion. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. Illumina's revenue was down 1.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.98 earnings per share. As a group, analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Insider Activity

In other Illumina news, CFO Ankur Dhingra bought 6,100 shares of the business's stock in a transaction on Monday, May 12th. The stock was bought at an average price of $81.21 per share, for a total transaction of $495,381.00. Following the completion of the transaction, the chief financial officer owned 24,906 shares in the company, valued at approximately $2,022,616.26. The trade was a 32.44% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 2.60% of the stock is owned by company insiders.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.